Episode Details

Medtronic plc (MDT) Q1 FY2027 — Shares closed $92.04, up 1.5%, after opening at $94.00 and giving most of the pop back. Fiscal 2027 is a 53-week year and the extra week landed in Q1. Medtronic's own footnote puts it at $570m - 49% of the entire organic revenue increase. Strip it out and organic growth is 7.0%, not 13.7%, which is below the bottom of the 7.25-7.75% full-year guide the company raised on the same page. THE CALL: HOLD (3/5, MODERATE) — base-case value ~$89.39 vs ~$92.04 today. KEY METRICS: - Revenue $9.756bn, up 13.7% reported and 13.7% organic - but the 53rd week supplied $570m of it - Ex-week organic growth 7.0%, below the raised 7.25-7.75% FY2027 guide - Adjusted EPS $1.45 vs $1.39 consensus - a 6c beat, but only a 2c raise at the FY guide midpoint - Adjusted operating margin 23.7%, up just 10bp on 13.7% revenue growth (incremental margin 24.7%) - R&D grew 6.2% vs revenue 13.7% - 56bp of margin relief, 5.6x the margin actually delivered - GAAP EPS $1.14 (+40.7%), but +22.5% once the minority-investment mark is stripped from both years - Free cash flow $1.290bn, up 120.9%; operating cash flow $1.793bn on flat capex - Electrophysiology $2.218bn, +29.1% organic and +41.1% in the US - 44% of the organic increase - Fair value $89.39 vs $92.04 close (-2.9%); Street consensus $95.54, median $97 What to watch: Q2 FY2027 on 17 November has no extra week in it. Organic growth near 7% confirms the base case; a five confirms the bear. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.